1. Pink Sheet

AstraZeneca’s COVID Vaccine US Filing Is Delayed – Really Delayed. Here Are Two Theories Why

 
• By Derrick Gingery

Based on the historical time between Phase III results and filing announcements, AstraZeneca is way behind the pace. The firm will soon have waited longer to submit its EUA to the US FDA than the three already-authorized products waited combined.

Aerial overhead view of trailer trucks delivering a vaccine. 3D rendering
AstraZeneca has now waited longer to file an EUA request for its COVID-19 shot than the FDA took to authorize any of the three vaccines already being used in the US. • Source: Shutterstock

AstraZeneca PLC still intends to apply for a US Food and Drug Administration emergency use authorization of its coronavirus vaccine, but preparations are taking longer than predecessors, potentially influenced by the appearance of rare blood clots among recipients.

Thirty-one days have passed since the company announced positive interim Phase III data for its proposed vaccine, AZD1222, on 22 March

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Vaccines

More from Pink Sheet